Neal Scott
Cardiovascular Disease · Mountain View, CANPI 1386669455
Payments from drug & device makers
Across 136 payments — averaging $35.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pulse Biosciences, Inc.$2K
- Abbott$451
- Amgen$365
- Esperion Therapeutics, Inc.$352
- Novartis$321
- Pfizer$202
- plus $1K from 18 others
What the payments were for
- Consulting fees$1,62534%
- Food & beverage$3,17866%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pulse Biosciences, Inc. | 1 | $1,625 |
| Abbott | 12 | $451 |
| Amgen | 15 | $365 |
| Esperion Therapeutics, Inc. | 16 | $352 |
| Novartis | 16 | $321 |
| Pfizer | 9 | $202 |
| Johnson & Johnson | 11 | $194 |
| Kiniksa Pharmaceuticals, Ltd. | 7 | $157 |
| Bardy Diagnostics, Inc. | 6 | $153 |
| Biotronik Inc. | 1 | $131 |
| AstraZeneca | 6 | $106 |
| Alnylam Pharmaceuticals Inc. | 4 | $98 |
| E.r. Squibb & Sons, L.L.C. | 5 | $98 |
| Novo Nordisk | 6 | $98 |
| Baxter Healthcare | 3 | $82 |
| Boehringer Ingelheim | 3 | $68 |
| Astellas Pharma US Inc | 3 | $65 |
| Kowa Pharmaceuticals America, Inc. | 3 | $48 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $42 |
| Cathworks, Inc. | 1 | $40 |
| Sanofi-aventis U.S. LLC | 2 | $39 |
| Amarin Pharma, Inc. | 2 | $38 |
| Atricure, Inc. | 1 | $16 |
| Medtronic | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CellFX$1,625
- Quadra Assura CRT Defibrillator$123
How this compares
$4,803 in reported general payments places this provider in the 60th percentile of 2,184 cardiovascular disease providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 32 | $52,813 |
| XareltoRivaroxaban | 17 | $24,846 |
| Repatha SureclickEvolocumab | 14 | $17,496 |
| Potassium Chloride | 24 | $847 |
| Losartan Potassium | 37 | $715 |
| Rosuvastatin Calcium | 46 | $711 |
| Metoprolol Succinate | 48 | $658 |
| Atorvastatin Calcium | 52 | $604 |
| Amlodipine Besylate | 36 | $540 |
| Ezetimibe | 16 | $343 |
| Lisinopril | 23 | $315 |
| Carvedilol | 11 | $221 |
| Doxazosin Mesylate | 11 | $143 |
| Hydrochlorothiazide | 12 | $60 |
| Triamterene-HydrochlorothiazidTriamterene/Hydrochlorothiazid | 14 | $57 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $202 | $52,81332 claims |
| Johnson & JohnsonXarelto | $194 | $24,84617 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,184 cardiovascular disease providers in California.
Other cardiovascular disease in Mountain View
- Ted LoveHillsborough$102.8M
- Matthew BudoffTorrance$11.3M
- Lori DanielsSan Diego$10.2M
- Paul KurthSanta Barbara$6.1M
- Michael BlumSan Francisco$5.5M
- Tony ChouSan Francisco$5.2M
- Jason RogersSacramento$5.1M
- Yu-Ping WangStanford$3.8M
- Yogesh PaliwalPomona$3.3M
- Farhad RafiiWest Hills$3.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.